Trial Condition(s):

Hyperphosphatemia

Fosrenol post-marketing surveillance for continuous cyclic peritoneal dialysis in Japan (FOSRENOL-CAPD)

Bayer Identifier:

15076

ClinicalTrials.gov Identifier:

NCT01412398

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CAPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.

Inclusion Criteria
-  Patients undergoing continuous ambulatory peritoneal dialysis who received Fosrenol for hyperphosphatemia
Exclusion Criteria
-  Patients who are contraindicated based on the product label

Trial Summary

Enrollment Goal
446
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Fosrenol (Lanthanum Carbonate, BAY77-1931)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design